Abstract
Ceftazidime (CAZ, SN 401), a new parenteral cepharosporin derivative, was given to 19 adult patients. Clinical efficacy of this drug was assessable in 16 patients with various infections, consisting of 14 cases of respiratory tract infections such as bronchopneumonia (10), chronic bronchitis (2), acute bronchitis (1) and pulmonary suppuration (1), and 2 cases of sepsis suspected. CAZ was given intravenously at a dose of 2-4 g/day. The cumulative clinical and bacteriological efficacy was obtained in 12 out of the 16 patients (75%): excellent in 4, good in 8 and poor in 4.
In the bacteriological study, P. aeruginosa isolated from sputum was decreased or eradicated in 4 out of 6 cases, and H. influenzae, K. pneumoniae, E. coli, and Citrobacter sp. were eradicated in all the cases by the administration of CAZ.
These results suggest that CAZ has clinical efficacy in GNR infections including those caused by P. aeruginosa.
Slight elevation of serum GPT level was observed in 2 patients, and skin rash and eosinophilia were noted in 1 case. No other side effects were observed.
